Asciminib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.602
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Asciminib. Strongest target: ABL2_ARG at 30.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL2_ARG | 30.7% | 69.3% |
| 2 | NEK11 | 19.7% | 80.3% |
| 3 | PDK2_PDHK2 | 16.7% | 83.3% |
| 4 | ASK1_MAP3K5 | 16.4% | 83.6% |
| 5 | AURORA_A | 15.3% | 84.7% |
| 6 | MAPKAPK2 | 15.3% | 84.7% |
| 7 | WNK3 | 14.9% | 85.1% |
| 8 | ERK2_MAPK1 | 14.4% | 85.6% |
| 9 | EPHA6 | 13.8% | 86.2% |
| 10 | BMPR2 | 13.7% | 86.3% |
| 11 | RIPK2 | 13.6% | 86.4% |
| 12 | NEK4 | 13.5% | 86.5% |
| 13 | ARAF | 13.1% | 86.9% |
| 14 | PIM2 | 12.8% | 87.2% |
| 15 | TRKB | 12.8% | 87.2% |
| 16 | WNK1 | 12.4% | 87.6% |
| 17 | MARK3 | 12.4% | 87.6% |
| 18 | CDK17_CYCLIN_Y(PCTK2) | 12.3% | 87.7% |
| 19 | ERN2_IRE2 | 12.2% | 87.8% |
| 20 | SGK3_SGKL | 12.2% | 87.8% |
Selectivity landscape
Where Asciminib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Asciminib.
Atlas insights for Asciminib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.873 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.849 |
| SRR12202498 | — | 0.838 |
| SRR1443713 | GTEX | 0.836 |
| R247 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…